BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 25899401)

  • 21. Reduced Risk of Sinusoidal Obstruction Syndrome of the Liver after Busulfan-Cyclophosphamide Conditioning Prior to Allogeneic Hematopoietic Stem Cell Transplantation.
    El-Serafi I; Remberger M; Ringdèn O; Törlén J; Sundin M; Björklund A; Winiarski J; Mattsson J
    Clin Transl Sci; 2020 Mar; 13(2):293-300. PubMed ID: 31675173
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Incidence, Predictors, and Outcomes of Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation.
    Lewis C; Kim HT; Roeker LE; Cutler C; Koreth J; Nikiforow S; Armand P; Gootpu M; Romee R; Glotzbecker B; Nageshwar P; Antin JH; Alyea EP; Richardson P; Soiffer RJ; Ho VT
    Biol Blood Marrow Transplant; 2020 Mar; 26(3):529-539. PubMed ID: 31678537
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hepatic sinusoidal obstruction syndrome after allogeneic hematopoietic stem cell transplantation in adult patients with idiopathic aplastic anemia.
    Kim H; Lee KH; Sohn SK; Jung CW; Joo YD; Kim SH; Kim BS; Choi JH; Kwak JY; Kim MK; Bae SH; Shin HJ; Won JH; Oh S; Lee WS; Park JH; Yoon SS
    Leuk Res; 2013 Oct; 37(10):1241-7. PubMed ID: 23871157
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Autologous stem cell transplantation for Hodgkin's disease: busulfan, melphalan and thiotepa compared to a radiation-based regimen.
    Gutierrez-Delgado F; Holmberg L; Hooper H; Petersdorf S; Press O; Maziarz R; Maloney D; Chauncey T; Appelbaum F; Bensinger W
    Bone Marrow Transplant; 2003 Aug; 32(3):279-85. PubMed ID: 12858199
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase II study of high-dose busulfan, melphalan and thiotepa with autologous peripheral blood stem cell support in patients with malignant disease.
    Schiffman KS; Bensinger WI; Appelbaum FR; Rowley S; Lilleby K; Clift RA; Weaver CH; Demirer T; Sanders JE; Petersdorf S; Gooley T; Weiden P; Zuckerman N; Montgomery P; Maziarz R; Klarnet JP; Rivkin S; Trueblood K; Storb R; Holmberg L; Buckner CD
    Bone Marrow Transplant; 1996 Jun; 17(6):943-50. PubMed ID: 8807098
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Busulfan, cyclophosphamide, and etoposide as high-dose conditioning regimen in patients with malignant lymphoma.
    Hänel M; Kröger N; Sonnenberg S; Bornhäuser M; Krüger W; Kroschinsky F; Hänel A; Metzner B; Birkmann J; Schmid B; Hoffknecht MM; Fiedler F; Ehninger G; Zander AR
    Ann Hematol; 2002 Feb; 81(2):96-102. PubMed ID: 11907790
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Outcomes of Consecutively Diagnosed Primary Central Nervous System Lymphoma Patients Using the Alberta Lymphoma Clinical Practice Guideline Incorporating Thiotepa-Busulfan Conditioning for Transplantation-Eligible Patients.
    Sanders S; Chua N; Larouche JF; Owen C; Shafey M; Stewart DA
    Biol Blood Marrow Transplant; 2019 Aug; 25(8):1505-1510. PubMed ID: 30965138
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High-dose Thiotepa, Busulfan, Cyclophosphamide, and Autologous Stem Cell Transplantation as Upfront Consolidation for Systemic Non-Hodgkin Lymphoma With Synchronous Central Nervous System Involvement.
    Qualls D; Sullivan A; Li S; Brunner AM; Collier K; Hochberg E; Armand P; Batchelor TT; Chen YB; DeFilipp Z
    Clin Lymphoma Myeloma Leuk; 2017 Dec; 17(12):884-888. PubMed ID: 28870642
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Thiotepa, busulfan and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced chronic myelogenous leukemia.
    Przepiorka D; Khouri I; Thall P; Mehra R; Lee MS; Ippoliti C; Giralt S; Gajewski J; van Besien K; Andersson B; Körbling M; Deisseroth AB; Champlin R
    Bone Marrow Transplant; 1999 May; 23(10):977-81. PubMed ID: 10373061
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An expanded-access clinical study of thiotepa (DSP-1958) high-dose chemotherapy before autologous hematopoietic stem cell transplantation in patients with malignant lymphoma.
    Nishikori M; Masaki Y; Fujii N; Ikeda T; Takahara-Matsubara M; Sugimoto S; Kondo E
    Int J Hematol; 2022 Mar; 115(3):391-398. PubMed ID: 34826108
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Prognostic Significance of Elevated Serum Ferritin Levels Prior to Transplantation in Patients With Lymphoma Who Underwent Autologous Hematopoietic Stem Cell Transplantation (autoHSCT): Role of Iron Overload.
    Sivgin S; Karamustafaoglu MF; Yildizhan E; Zararsiz G; Kaynar L; Eser B; Cetin M; Unal A
    Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S152-8. PubMed ID: 27521313
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma.
    Nagler A; Slavin S; Varadi G; Naparstek E; Samuel S; Or R
    Bone Marrow Transplant; 2000 May; 25(10):1021-8. PubMed ID: 10828860
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hematopoietic stem cell transplantation for childhood myeloid malignancies after high-dose thiotepa, busulfan and cyclophosphamide.
    Worth L; Tran H; Petropoulos D; Culbert S; Mullen C; Roberts W; Przepiorka D; Chan K
    Bone Marrow Transplant; 1999 Nov; 24(9):947-52. PubMed ID: 10556952
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Morbidity and transplant-related mortality of CBV and BEAM preparative regimens for patients with lymphoid malignancies undergoing autologous stem-cell transplantation.
    Puig N; de la Rubia J; Remigia MJ; Jarque I; Martín G; Cupelli L; Sanz GF; Lorenzo I; Sanz J; Martínez JA; Jiménez C; Sanz MA
    Leuk Lymphoma; 2006 Aug; 47(8):1488-94. PubMed ID: 16966258
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Autologous transplantation for relapsed non-Hodgkin's lymphoma using intravenous busulfan and cyclophosphamide as conditioning regimen: a single center experience.
    Escalón MP; Stefanovic A; Venkatraman A; Pereira D; Santos ES; Goodman M; Byrnes JJ; Fernandez HF
    Bone Marrow Transplant; 2009 Jul; 44(2):89-96. PubMed ID: 19169287
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Earlier defibrotide initiation post-diagnosis of veno-occlusive disease/sinusoidal obstruction syndrome improves Day +100 survival following haematopoietic stem cell transplantation.
    Richardson PG; Smith AR; Triplett BM; Kernan NA; Grupp SA; Antin JH; Lehmann L; Miloslavsky M; Hume R; Hannah AL; Nejadnik B; Soiffer RJ
    Br J Haematol; 2017 Jul; 178(1):112-118. PubMed ID: 28444784
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Subacute hepatic necrosis mimicking veno-occlusive disease in a patient with HFE H63D homozygosity after allogeneic hematopoietic cell transplantation with busulfan conditioning.
    Chen S; Osborn JD; Chen X; Boyer MW; McDonald GB; Hildebrandt GC
    Int J Hematol; 2015 Dec; 102(6):729-31. PubMed ID: 26497867
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Thiotepa, busulfan, cyclophosphamide (TBC) and autologous hematopoietic transplantation: an intensive regimen for the treatment of multiple myeloma.
    Shimoni A; Smith TL; Aleman A; Weber D; Dimopoulos M; Anderlini P; Andersson B; Claxton D; Ueno NT; Khouri I; Donato M; Korbling M; Alexanian R; Champlin R; Giralt S
    Bone Marrow Transplant; 2001 Apr; 27(8):821-8. PubMed ID: 11477439
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High-Dose Melphalan Plus Thiotepa as Conditioning Regimen before Second Autologous Stem Cell Transplantation for "De Novo" Multiple Myeloma Patients: A Phase II Study.
    Musso M; Messina G; Marcacci G; Crescimanno A; Console G; Donnarumma D; Scalone R; Pinto A; Martino M
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):1932-8. PubMed ID: 26099830
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Sinusoidal obstruction syndrome after BeAM conditioning regiment for autologous stem cell transplantation: Imputability of bendamustine? Report of two cases and literature review].
    Meyer A; Fornecker LM; Guffroy A; Korganow AS; Martin M
    Rev Med Interne; 2018 Nov; 39(11):882-885. PubMed ID: 29673920
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.